See more : Uonlive Corporation (UOLI) Income Statement Analysis – Financial Results
Complete financial analysis of Aura Biosciences, Inc. (AURA) income statement, including revenue, profit margins, EPS and key performance metrics. Get detailed insights into the financial performance of Aura Biosciences, Inc., a leading company in the Biotechnology industry within the Healthcare sector.
You may be interested
- Tycoons Worldwide Group (Thailand) Public Company Limited (TYCN.BK) Income Statement Analysis – Financial Results
- Diploma PLC (DPLM.L) Income Statement Analysis – Financial Results
- Libero Copper & Gold Corporation (LBC.V) Income Statement Analysis – Financial Results
- Moncler S.p.A. (MONRY) Income Statement Analysis – Financial Results
- JSW Infrastructure Limited (JSWINFRA.BO) Income Statement Analysis – Financial Results
Aura Biosciences, Inc. (AURA)
About Aura Biosciences, Inc.
Aura Biosciences, Inc. operates as a biotechnology company that develops therapies to treat cancer. The company develops virus-like drug conjugates (VDC) technology platform for the treat tumors of high unmet need in ocular and urologic oncology. It develops AU-011, a VDC candidate for the treatment of primary choroidal melanoma. It also develops AU-011 in additional ocular oncology indications, including choroidal metastases. The company was incorporated in 2009 and is headquartered in Cambridge, Massachusetts.
| Metric | 2023 | 2022 | 2021 | 2020 | 2019 |
|---|---|---|---|---|---|
| Revenue | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Cost of Revenue | 1.30M | 1.18M | 835.00K | 831.00K | 509.00K |
| Gross Profit | -1.30M | -1.18M | -835.00K | -831.00K | -509.00K |
| Gross Profit Ratio | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% |
| Research & Development | 65.23M | 42.24M | 25.16M | 18.04M | 19.62M |
| General & Administrative | 19.76M | 18.06M | 10.09M | 4.16M | 4.52M |
| Selling & Marketing | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| SG&A | 19.76M | 18.06M | 10.09M | 4.16M | 4.52M |
| Other Expenses | 0.00 | -5.00K | -11.00K | 3.00K | -44.00K |
| Operating Expenses | 84.99M | 60.30M | 35.25M | 22.21M | 24.14M |
| Cost & Expenses | 84.99M | 60.30M | 35.25M | 22.21M | 24.14M |
| Interest Income | 0.00 | 1.86M | 13.00K | 3.00 | 5.00 |
| Interest Expense | 0.00 | 0.00 | 13.00K | 3.00K | 5.00K |
| Depreciation & Amortization | 1.30M | 1.18M | 835.00K | 831.00K | 509.00K |
| EBITDA | -83.70M | -59.12M | -34.42M | -21.38M | -23.63M |
| EBITDA Ratio | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% |
| Operating Income | -84.99M | -60.30M | -35.25M | -22.21M | -24.14M |
| Operating Income Ratio | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% |
| Total Other Income/Expenses | 8.72M | 1.53M | -1.00K | 0.00 | -60.00K |
| Income Before Tax | -76.27M | -58.76M | -35.25M | -22.21M | -24.20M |
| Income Before Tax Ratio | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% |
| Income Tax Expense | 137.00K | -1.53M | -830.00K | 3.00K | 5.00K |
| Net Income | -76.41M | -57.23M | -34.42M | -22.21M | -24.21M |
| Net Income Ratio | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% |
| EPS | -1.93 | -1.91 | -1.18 | -0.76 | -0.83 |
| EPS Diluted | -1.93 | -1.91 | -1.18 | -0.76 | -0.83 |
| Weighted Avg Shares Out | 39.62M | 29.94M | 29.21M | 29.22M | 29.22M |
| Weighted Avg Shares Out (Dil) | 39.62M | 29.94M | 29.21M | 29.22M | 29.22M |
Aura Biosciences Reports Topline Data from a Retrospective Study of Belzupacap Sarotalocan (AU-011) versus Plaque Radiotherapy Supporting the Value of a Vision Preserving Therapy for the Treatment of Patients with Early-Stage Choroidal Melanoma
CAMBRIDGE, Mass.--(BUSINESS WIRE)--Aura Biosciences Inc. (NASDAQ: AURA), a clinical-stage biotechnology company developing a novel class of virus-like drug conjugate (VDC) therapies for multiple oncology indications, reported results from a retrospective, matched case control study. This retrospective analysis assessed the visual...
Aura Biosciences to Present Updated Belzupacap Sarotalocan (AU-011) Data on Multiple Studies at the International Society of Ocular Oncology 2022 Bi-Annual Meeting
CAMBRIDGE, Mass.--(BUSINESS WIRE)--Aura Biosciences Inc. (NASDAQ: AURA), a clinical-stage biotechnology company developing a novel class of virus-like drug conjugate (VDC) therapies for multiple oncology indications, today announced multiple presentations of data evaluating its first VDC, belzupacap sarotalocan (AU-011), for the...
Aura Biosciences to Present Updated Belzupacap Sarotalocan (AU-011) Data on Multiple Studies at the International Society of Ocular Oncology 2022 Bi-Annual Meeting
CAMBRIDGE, Mass.--(BUSINESS WIRE)--Aura Biosciences Inc. (NASDAQ: AURA), a clinical-stage biotechnology company developing a novel class of virus-like drug conjugate (VDC) therapies for multiple oncology indications, today announced multiple presentations of data evaluating its first VDC, belzupacap sarotalocan (AU-011), for the...
Aura Biosciences Announces Publication of Preclinical Data of the Combination of VDCs with Immune Checkpoint Inhibitors at the 2022 ASCO Annual Meeting
CAMBRIDGE, Mass.--(BUSINESS WIRE)--Aura Biosciences Inc. (NASDAQ: AURA), a clinical-stage biotechnology company developing a novel class of virus-like drug conjugate (VDC) therapies for multiple oncology indications, today announced the publication of preclinical data on AU-011, its first VDC product candidate, in...
Aura Biosciences Announces Publication of Preclinical Data of the Combination of VDCs with Immune Checkpoint Inhibitors at the 2022 ASCO Annual Meeting
CAMBRIDGE, Mass.--(BUSINESS WIRE)--Aura Biosciences Inc. (NASDAQ: AURA), a clinical-stage biotechnology company developing a novel class of virus-like drug conjugate (VDC) therapies for multiple oncology indications, today announced the publication of preclinical data on AU-011, its first VDC product candidate, in...
Aura Biosciences to Participate in Upcoming Investor Conferences
CAMBRIDGE, Mass.--(BUSINESS WIRE)--Aura Biosciences Inc. (NASDAQ: AURA), a clinical-stage biotechnology company developing a novel class of virus-like drug conjugate (VDC) therapies for multiple oncology indications, today announced that members of its executive team will participate in the following upcoming investor...
Aura Biosciences Reports First Quarter 2022 Financial Results and Provides Clinical Development and Operational Highlights
CAMBRIDGE, Mass.--(BUSINESS WIRE)--Aura Biosciences Inc. (NASDAQ: AURA), a clinical-stage biotechnology company developing a novel class of virus-like drug conjugate (VDC) therapies for multiple oncology indications, today reported financial results for the first quarter ended March 31, 2022, and provided clinical...
Aura Biosciences Reports First Quarter 2022 Financial Results and Provides Clinical Development and Operational Highlights
CAMBRIDGE, Mass.--(BUSINESS WIRE)--Aura Biosciences Inc. (NASDAQ: AURA), a clinical-stage biotechnology company developing a novel class of virus-like drug conjugate (VDC) therapies for multiple oncology indications, today reported financial results for the first quarter ended March 31, 2022, and provided clinical...
Aura Biosciences Presents Preclinical Data Highlighting AU-011’s Anti-Tumor Activity in Choroidal Metastasis, an Additional Ocular Oncology Indication at the 2022 ARVO Annual Meeting
CAMBRIDGE, Mass.--(BUSINESS WIRE)--Aura Biosciences Inc. (NASDAQ: AURA), a clinical-stage biotechnology company developing a novel class of virus-like drug conjugate (VDC) therapies for multiple oncology indications, today announced the presentation of preclinical data for its first VDC product candidate, AU‑011. AU-011...
Aura Biosciences Presents Preclinical Data Highlighting AU-011's Anti-Tumor Activity in Choroidal Metastasis, an Additional Ocular Oncology Indication at the 2022 ARVO Annual Meeting
CAMBRIDGE, Mass.--(BUSINESS WIRE)--Aura Biosciences Inc. (NASDAQ: AURA), a clinical-stage biotechnology company developing a novel class of virus-like drug conjugate (VDC) therapies for multiple oncology indications, today announced the presentation of preclinical data for its first VDC product candidate, AU‑011. AU-011...
Source: https://incomestatements.info
Category: Stock Reports